Of note, when we assessed SCG3 levels in patients with and those without each respective single component of MetS, higher serum SCG3 levels were only found in subjects with high FPG (120.7 ± 75.5 vs. 84.9 ± 54.7 nmol/L, p < 0.001), elevated WC (111.3 ± 69.8 vs. 90.6 ± 60.4 nmol/L, p = 0.012), or hypertriglyceridemia (115.1 ± 73.6 vs. 92.4 ± 60.4 nmol/L, p = 0.025), but not elevated blood pressure (100.0 ± 66.0 vs. 94.3 ± 62.3 nmol/L, p = 0.53) or reduced HDL-C levels (105.6 ± 66.0 vs. 94.3 ± 62.3 nmol/L, p = 0.47) (Figure 2). Here, SCG3 is linked to hypertriglyceridemia.